nanosonics
Infection Prevention. For Life.

For personal use only

Appendix 4E

Preliminary Final Report – Results for Announcement to the Market

Name of entity: **NANOSONICS LIMITED**

ABN 11 095 076 896

Year ended: **30 June 2025**

Nanosonics Limited (the Company) gives the following information to ASX under listing rule 4.3A and Appendix 4E.

1 Reporting period: Year ended 30 June 2025

Prior corresponding period: Year ended 30 June 2024

2 Results for announcement to the market

		% change		$'000
Revenue	Up	16.83%	to	198,628
Earnings before interest and taxes	Up	95.33%[1]	to	17,808
Operating income before income tax	Up	71.62%[2]	to	22,287
Profit from ordinary activities after tax attributable to members	Up	59.39%[3]	to	20,676
Net profit for the period attributable to members	Up	59.39%[3]	to	20,676

Dividends	Amount per security	Franked amount per security
Interim dividend paid per share	-	-
Final dividend paid per share	-	-
Dividends proposed per share	-	-
Record date for entitlement to dividend proposed	n/a	n/a

Net Tangible Asset Backing	**30 June 2025**	**30 June 2024**
Net tangible asset backing per ordinary security on issue at period end[4]:	62.96 cents	54.68 cents

1. In the prior corresponding period, the Company had an earnings before interest and taxes of $9,117,000 compared to this period's $17,808,000 earnings before interest and taxes.
2. In the prior corresponding period, the Company had an operating profit before tax of $12,986,000 compared to this period's $22,287,000 operating profit before tax.
3. In the prior corresponding period, the Company had a consolidated profit after tax of $12,972,000 compared to this period's $20,676,000 consolidated profit after tax.
4. Net tangible asset backing per ordinary security calculation include right-of-use asset. If right-of-use asset was excluded, the net tangible asset backing per ordinary security on issue at period end would have been 60.70 cents (2024: 51.91cents).

For personal use only

The Nanosonics Limited audited Annual Report for the year ended 30 June 2025 accompanies this announcement.

Additional Appendix 4E disclosure requirements can be found in the Directors' report, the review of operations and the 30 June 2025 financial statements and accompanying notes in the Annual Report.

Where applicable, the Annual Report includes information per items 3 to 16 below:

3 Consolidated statement of profit or loss and other comprehensive income together with notes to the statement, prepared in compliance with AASB 101 Presentation of Financial Statements.

4 Consolidated statement of financial position together with notes to the statement.

5 Consolidated statement of cash flows together with the notes to the statement, prepared in compliance with AASB 107 Statement of Cash Flows.

6 Consolidated statement of changes in equity showing retained earnings/(accumulated losses) and movements during the year.

7 Details of dividends are shown in the Directors' report and in note 2.7 to the financial statements. No dividends were proposed, declared or paid during the reporting period and the prior corresponding period.

8 No dividend or distribution reinvestment plans operated during the reporting period and the prior corresponding period.

9 Net tangible assets per security with the comparative figure for the prior corresponding period is noted in the table in item 2 above.

10 No control has been gained or lost over any other entities during the period ended 30 June 2025.

11 The entity had no associates or joint venture entities during the period or the prior corresponding period.

12 Other significant information is available in the Annual Report for the year ended 30 June 2025 that accompanies this announcement.

13 Nanosonics Limited is an Australian company which applies Australian Accounting Standards and also complies with International Financial Reporting Standards.

14 A commentary on the results for the period is available in the Financial and Operational Review on pages 8 to 15 of the Annual Report. Other relevant information is as follows:

		2025	2024
14.1	Earnings per share	**cents**	cents
	Basic earnings per share	**6.82**	4.29
	Diluted earnings per share	**6.69**	4.20

Details of earnings per share are shown in note 2.6 to the financial statements.

14.2 There were no returns to shareholders during the period or the prior corresponding period.

14.3 Significant features of operating performance are included in the Annual Report.

14.4 The entity has one business segment, being healthcare equipment and operates in three geographical regions – North America, Europe, UK and the Middle East and Asia Pacific. Segment information is included in note 2.2 to the financial statements.

15 The financial statements included in the Annual Report have been audited and the Auditor's report appears on pages 60 to 104.

16 The financial statements included in the Annual Report are not subject to audit dispute or qualification.

Directors' resolution

The information set out above and in the Annual Report accompanies this announcement is provided to ASX in accordance with a resolution of the directors dated 26 August 2025.

Signed: Date: 26 August 2025

Print name: Jason Burriss
CFO

For personal use only

For personal use only